Canada’s PMPRB releases annual report

The Patented Medicines Pricing Review Board in Canada has released its annual report for 2017.

It reported a moderate 7.6% increase in sales over the previous year, with prices not increasing. Canadian price levels are mid-ranked against reference countries, at approximately 5% more than the UK and 25% more than France, but 10% less than Germany.

The organisation reviewed the prices of 59 of the 80 medicines new in 2017, and found 11 exceeded its price guidelines. Of these 5 have resulted in negotiated price-reduction agreements (VCUs).

R&D expenditure from companies working through PMPRB fell 5% to $870 million, falling from 4.4% of sales to 4.1%.

The full report can be found here.

Tagged with

Published 29. August 2018 in News, News Canada